Serum Glucan Levels Are Not Specific for Presence of Fungal Infections in Intensive Care Unit Patients
- 1 September 2003
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 10 (5), 882-885
- https://doi.org/10.1128/cdli.10.5.882-885.2003
Abstract
Fungal infections in the critically ill patient are difficult to diagnose and are associated with a high mortality rate. A major obstacle to managing fungal infection is the lack of a reliable clinical assay that will rapidly identify patients with fungal sepsis. Glucans are polymers of glucose that are found in the cell wall of fungi and certain bacteria. Glucans are also released from the fungal cell wall into the extracellular milieu. Several studies have reported that detection of fungal glucan in serum or plasma is useful in the diagnosis of mycoses. However, recent studies have questioned the clinical utility of this assay. In this study, we examined serum glucan levels in intensive care unit (ICU) patients and attempt to correlate serum glucan levels with the presence of fungal infection. Following attainment of informed consent, serum was harvested from 46 ICU patients with confirmed fungal infections, confirmed bacterial infections, or no evidence of infection. Sera from eight healthy volunteers served as control. Serum glucan was assayed with a glucan-specific Limulus assay. Serum glucan levels were increased (69.6 ± 17 pg/ml; P < 0.001) in ICU patients versus the normal (11.5 ± 1.3 pg/ml) and noninfected ICU (27.4 ± 17 pg/ml) controls. However, serum glucan levels were not different in patients with confirmed fungal infections versus those with confirmed bacterial infections. Thus, serum glucan levels did not show a correlation with the presence of fungal infections and do not appear to be specific for fungal infections. However, the assay may be useful as a negative predictor of infection.Keywords
This publication has 14 references indexed in Scilit:
- Diagnosis of fungal infections: current statusJournal of Antimicrobial Chemotherapy, 2002
- Opportunistic fungal infections in the critically ill.2000
- Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients.2000
- Evaluation of a New Laboratory Test Measuring Plasma (1-3)-^|^beta;-D-glucan in the Diagnosis of Candida Deep MycosisKansenshogaku Zasshi, 1999
- [The Clinical Significance of Plasma]1998
- Detection of plasma (1 → 3)-β-d-glucan in patients withFusarium, Trichosporon, SaccharomycesandAcremoniumfungaemiasMedical Mycology, 1997
- Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodesThe Lancet, 1995
- Improved survival from fungaemia in patients with haematological malignancies: Analysis of risk factors for death and usefulness of early antifungal therapyEuropean Journal of Haematology, 1993
- An Evaluation of Serodiagnostic Tests in Patients with Candidemia: Beta‐Glucan, Mannan, Candida Antigen by Cand‐Tec and D‐ArabinitolMicrobiology and Immunology, 1993
- Relationship between conformation and biological response for (1→3)-β-d-glucans in the activation of coagulation Factor G from limulus amebocyte lysate and host-mediated antitumor activity. Demonstration of single-helix conformation as a stimulant.Carbohydrate Research, 1991